๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Systemic Sclerosis (SSc)
Clinical trial register · China

Systemic Sclerosis (SSc) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 11 Hefei 3 Guangzhou 3 Wuhan 3 Shanghai 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing11 Hefei3 Guangzhou3 Wuhan3 Shanghai3
All 14 locations
Target enrolment
to

Systemic Sclerosis (SSc) trials in China

22 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
NCT07523282Autoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)
DrugHN2302
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1
12
Hefei
2026-12-31
Not yet open
Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
NCT07806045IgG4 Related Disease, Systemic Sclerosis (SSc)
Qiubai Li
Phase EARLY_PHASE1
18
Beijing
2026-10-14
Not yet open
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases
Antengene Biologics Limited
Phase 1
149
Bengbu, Hefei, Beijing, Xiamen, Guangzhou, Luoyang, Zhengzhou, Wuhan
2026-09-01
Not yet open
A Phase II Study of TollB-001 Tablets in Systemic Sclerosis
NCT07745725Systemic Sclerosis (SSc)
Toll Biotech Co. Ltd. (Beijing)
Phase 2
36
Beijing
2026-08
Recruiting
MTS109 in Patients With Refractory Autoimmune Diseases
NCT07526350Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc), ANCA-Associated Vasculitis (AAV)
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
15
Shanghai
2026-03-24
Recruiting
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
NCT07413341Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy
Therorna
Phase 1
12
Shanghai
2026-01-22
Recruiting
Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis
NCT07360808Systemic Sclerosis (SSc), Hand Dysfunction
Cytori Therapeutics
Not applicable
48
Guangzhou, Shanghai
2025-12-31
Recruiting
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
NCT07641634Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma
Prolium Bioscience, Inc
Phase 1/2
44
Beijing, Guangzhou, Nanchang, Nanjing, Pingxiang
2025-10-27
Recruiting
A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
NCT07167537Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
Beijing GoBroad Hospital
Phase 1
44
Beijing
2025-10
Recruiting
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
NCT07184450Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
Chongqing Precision Biotech Co., Ltd
Phase 1
11
Hangzhou
2025-09-01
Recruiting
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07104721Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Hefei
2025-08-04
Recruiting
Safety and Efficacy of Universal CD19-targeting CAR-ฮณฮดT Cells in Refractory Autoimmune Diseases
NCT06828042Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV)
Peking University Third Hospital
Phase 1/2
9
Beijing
2025-07-01
Not yet open
Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.
NCT06982534Systemic Sclerosis (SSc)
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1
24
Wuhan
2025-06
Recruiting
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
NCT06980597Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV)
Beijing GoBroad Hospital
Phase 1
44
Beijing
2025-06
Recruiting
The Clinical Study on the Treatment of SSc With UTAA91 Injection.
NCT07000682Systemic Sclerosis (SSc)
DrugUTAA91
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
24
Wuhan
2025-05-30
By invitation
Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
NCT07188285Systemic Lupus Erthematosus, Sjogren's Syndrome, Inflammatory Myopathies, Systemic Sclerosis (SSc)
Peking University People's Hospital
Observational
500
Beijing
2025-05-25
Recruiting
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
NCT06978647Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
12
Beijing
2025-05-19
Recruiting
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
NCT06822881Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Beijing GoBroad Hospital
Phase 1
27
Beijing
2025-02-20
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
NCT06941129Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA-Associated Vasculitis (AAV)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-02-11
Recruiting
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NCT06614270Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM), Sjogren's Syndrome
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
15
Hangzhou
2025-01-06
Recruiting
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
NCT06794008Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
Peking University People's Hospital
Phase 2
50
Beijing
2024-12-26
Recruiting
Safety Study of CC312 in Autoimmune Disease Patients
NCT06888960Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
DrugCC312
CytoCares Inc
Phase EARLY_PHASE1
18
Tianjin
2024-11-08
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/systemic-sclerosis-ssc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies listing the condition Systemic Sclerosis (SSc).

How many Systemic Sclerosis (SSc) trials are recruiting in China?

16 of the 22 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 0 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Systemic Sclerosis (SSc)), 22 studies
PhaseStudiesRecruitingShare
Phase 110845.5%
Phase EARLY_PHASE15322.7%
Not applicable229.1%
Phase 1/2229.1%
Phase 2219.1%
Observational104.5%

Most active sponsors

Lead sponsors with the most studies (Systemic Sclerosis (SSc))
Lead sponsorStudiesRecruiting
Beijing GoBroad Hospital33
China Immunotech (Beijing) Biotechnology Co., Ltd.22
Peking University People's Hospital21
Antengene Biologics Limited10
Chongqing Precision Biotech Co., Ltd11
CytoCares Inc11
Cytori Therapeutics11
Institute of Hematology & Blood Diseases Hospital, China11
Peking University Third Hospital11
PersonGen BioTherapeutics (Suzhou) Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.